Describe the mechanism of action.
The exact mechanism is unknown.
Exerts local (rather than systemic) anti-inflammatory effects in the GI tract.
May reduce inflammation in the colon by inhibiting cyclooxygenase and lipoxygenase, which catalyze the formation of prostaglandin precursors (endoperoxides) and of leukotrienes and hydroxyeicosatetraenoic acids, respectively, from arachidonic acid and/or its metabolites.
Extended-release capsules (Pentasa®), delayed-release tablets (1.2-g; Lialda®), rectal suppositories (Canasa®): Known hypersensitivity to salicylates (including aspirin, mesalamine) [ref] or any ingredient in the respective formulation.
List common adverse events.
Oral therapy: Headache, rash, vomiting, diarrhea, flatulence, constipation, nausea, dyspepsia, abdominal pain, fever, arthralgia, flu syndrome.
Rectal therapy: Headache, abdominal pain, nausea, diarrhea, gas/flatulence, fever, dizziness, rectal pain, rash, leg/joint pain, flu syndrome.